VV169, an experimental cellular therapy being developed by Vyriad to treat myeloma, is expected to enter clinical testing in 2026, the…
News
Immuneering is preparing to launch a Phase 3 clinical trial to test its experimental therapy, atebimetinib, in people with…
The first participant has been dosed in an early clinical trial testing the experimental radiation therapy Alpha DaRT in people with hard-to-treat glioma. The…
A Phase 1 clinical trial testing the experimental therapy IDE034 in people with various types of cancer, including gynecological cancers, is expected to start…
Johnson & Johnson (J&J) is asking the U.S. Food and Drug Administration (FDA) to approve a combination of two medications, Tecvayli (teclistamab) and…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to SENTI-202, Senti Biosciences‘ experimental cell therapy being developed…
Treatment with the experimental medication eflornithine in combination with the approved chemotherapy Gleostine (lomustine) may help improve survival in people with aggressive astrocytoma carrying IDH…
Dosing has begun in a Phase 3 clinical trial testing Enhertu (trastuzumab deruxtecan) as a maintenance treatment for certain people with ovarian cancer. The…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the experimental medicine CLN-049, which is being developed as a potential treatment…
Oncolytics Biotech has cleared a significant hurdle in the U.S. to advance its unique viral immunotherapy, pelareorep, to a pivotal Phase 3 trial for…
